Literature DB >> 3066538

The interleukins in acquired disease.

M Malkovský1, P M Sondel, W Strober, A G Dalgleish.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 3066538      PMCID： PMC1541799     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  110 in total

1.  B cell growth and differentiation induced by supernatants of transformed epithelial cell lines.

Authors:  F C Rawle; J Shields; S H Smith; V Iliescu; M Merkenschlager; P C Beverley; R E Callard
Journal:  Eur J Immunol       Date:  1986-08       Impact factor: 5.532

2.  Cloning of complementary DNA encoding T-cell replacing factor and identity with B-cell growth factor II.

Authors:  T Kinashi; N Harada; E Severinson; T Tanabe; P Sideras; M Konishi; C Azuma; A Tominaga; S Bergstedt-Lindqvist; M Takahashi
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

3.  Autologous lymphoid cells exposed to recombinant interleukin-2 in vitro in the absence of antigen can induce the rejection of long-term tolerated skin allografts.

Authors:  B Loveland; R Hunt; M Malkovský
Journal:  Immunology       Date:  1986-09       Impact factor: 7.397

4.  Acquired defect in interleukin-2 production in patients with type I diabetes mellitus.

Authors:  W A Kaye; M N Adri; J S Soeldner; S L Rabinowe; A Kaldany; C R Kahn; B Bistrian; S Srikanta; O P Ganda; G S Eisenbarth
Journal:  N Engl J Med       Date:  1986-10-09       Impact factor: 91.245

5.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

6.  High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings.

Authors:  M T Lotze; A E Chang; C A Seipp; C Simpson; J T Vetto; S A Rosenberg
Journal:  JAMA       Date:  1986-12-12       Impact factor: 56.272

7.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

8.  Human IL-3 (multi-CSF): identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3.

Authors:  Y C Yang; A B Ciarletta; P A Temple; M P Chung; S Kovacic; J S Witek-Giannotti; A C Leary; R Kriz; R E Donahue; G G Wong
Journal:  Cell       Date:  1986-10-10       Impact factor: 41.582

9.  Mechanisms of transplantation tolerance in B-cell-chimeric chickens. Impairment of tolerance by T cell growth factor.

Authors:  L Lehtonen; O Vainio; P Toivanen
Journal:  Transplantation       Date:  1986-08       Impact factor: 4.939

10.  Tumor necrosis factor and lymphotoxin induce differentiation of human myeloid cell lines in synergy with immune interferon.

Authors:  G Trinchieri; M Kobayashi; M Rosen; R Loudon; M Murphy; B Perussia
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307
View more
  16 in total

1.  Mononuclear cells from HIV-infected patients produce factors which enhance functional activity of polymorphonuclear neutrophils from healthy subjects.

Authors:  D I Gabrilovich; G K Shepeleva; L V Serebrovskaya; L A Avdeeva; Z K Suvorova; I M Rosly; V K Oganezov; M Z Saidov; A V Panyutich; V V Pokrovsky
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

2.  Evaluation of serum levels of tumour necrosis factor-alpha (TNF-alpha) and soluble IL-2 receptor (sIL-2R) and CD4, CD8 and natural killer (NK) populations during infrared pulsed laser device (IPLD) treatment.

Authors:  L A Santana-Blank; M Castes; M E Rojas; F Vargas; D Scott-Algara
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

3.  Lymphocytic choriomeningitis virus-induced immunodepression: inherent defect of B and T lymphocytes.

Authors:  M F Saron; B Shidani; M A Nahori; J C Guillon; P Truffa-Bachi
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

4.  Severe T lymphocyte immunodeficiency associated with hypogammaglobulinemia: defective lymphokine secretion but enhanced autologous mixed lymphocyte reaction.

Authors:  S Raziuddin; B Teklu
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

Review 5.  Roles of iron in neoplasia. Promotion, prevention, and therapy.

Authors:  E D Weinberg
Journal:  Biol Trace Elem Res       Date:  1992-08       Impact factor: 3.738

6.  Peripheral T-cell lymphomas. Immunophenotype, lymphokine production, and immunologic functional characteristics of the lymph-node malignant T cells.

Authors:  S Raziuddin; T Malatani; S al-Sedairy; A H al-Saigh
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

7.  Characterization of cytokine production in infectious mononucleosis studied at a single-cell level in tonsil and peripheral blood.

Authors:  J Andersson; U Andersson
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

8.  In vitro interleukin-1 (IL-1) production in thymic hyperplasia and thymoma from patients with myasthenia gravis.

Authors:  C Aime; S Cohen-Kaminsky; S Berrih-Aknin
Journal:  J Clin Immunol       Date:  1991-09       Impact factor: 8.317

9.  Tumour necrosis factor alpha and interleukin-2 in plasma from rheumatoid arthritis patients in relation to disease activity.

Authors:  G T Espersen; M Vestergaard; E Ernst; N Grunnet
Journal:  Clin Rheumatol       Date:  1991-12       Impact factor: 2.980

10.  Impairment of T-cell growth-promoting lymphokines in human insulin-dependent diabetes mellitus.

Authors:  G Valerio; N Gasparini; R Badolato; S Di Maio; A Tenore
Journal:  Acta Diabetol       Date:  1994-04       Impact factor: 4.280
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.